Changes in the expression profile of serum lncRNAs in pregnant women with high hepatitis B viral load during antiviral and non-antiviral treatment

Changes in the expression profile of serum lncRNAs in pregnant women with high hepatitis B viral load during antiviral and non-antiviral treatment

This research analyzes the potential of long non-coding RNAs (lncRNAs) as markers in determining the necessity of antiviral treatment in pregnant women by examining alterations in the expression profile of serum lncRNAs in pregnant women with elevated hepatitis B viral load (HBVL) under antiviral an...

Full description

Saved in:
Bibliographic Details
Published in:BMC pregnancy and childbirth Vol. 24; no. 1; pp. 696 - 8
Main Authors: Wang, Cuimin, Liang, Xuxia, Jia, Zaiming, Huang, Yuting, Chen, Hui, Wei, Haitang, Huang, Yin, Huang, Xizhen, Fang, Xiang
Format: Journal Article
Language:English
Published: England BioMed Central 24-10-2024
BMC
Subjects:
Adult
Antiviral Agents - therapeutic use
Antiviral drugs
Biomarkers - blood
Biosynthesis
Ethics
Fatty acids
Female
Gene Expression Profiling - methods
Genes
Hepatitis B
Hepatitis B - blood
Hepatitis B - drug therapy
Hepatitis B viral load
Hepatitis B virus - genetics
Hippo pathway
Humans
Infections
LncRNAs
Metabolism
Perinatal transmission
Postpartum period
Pregnancy
Pregnancy Complications, Infectious - blood
Pregnancy Complications, Infectious - drug therapy
Pregnancy Complications, Infectious - virology
Pregnancy Trimester, Second - blood
Prevention
RNA, Long Noncoding - blood
Thyroid gland
Viral Load
Womens health
Hippo pathway
Hepatitis B viral load
Perinatal transmission
LncRNAs
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This research analyzes the potential of long non-coding RNAs (lncRNAs) as markers in determining the necessity of antiviral treatment in pregnant women by examining alterations in the expression profile of serum lncRNAs in pregnant women with elevated hepatitis B viral load (HBVL) under antiviral and non-antiviral treatment regimens between the second trimester and delivery. Serum was obtained from 6 s-trimester pregnant women with high HBVL and no intrauterine infection. Then, 3 of these women were randomly selected for antiviral treatment, with the remaining 3 women undergoing non-antiviral treatment as control. Serum samples were again collected from these 6 women before delivery. The expression profile of lncRNAs was analyzed with microarray technology, followed by Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. The axes of hub lncRNA-miRNA-mRNA were identified based on the competing endogenous RNA (ceRNA) network. The expression profile of serum lncRNAs in pregnant women with high HBVL changed significantly from the second trimester of pregnancy until delivery under antiviral or non-antiviral treatment. The Venn diagram was utilized to screen out the jointly up-regulated and down-regulated lncRNAs in the serum of pregnant women under antiviral and non-antiviral treatment before delivery. Additionally, the KEGG pathway enrichment analysis results showed that lncRNAs might mediate the Hippo pathway in HBV infection. Based on the ceRNA network, 3 hub lncRNAs (CATG00000076041.1, LINC01310, and G014655) were found to potentially regulate the key gene TP73 in the Hippo pathway. In this study, we retrieved co-differentially expressed lncRNAs in pregnant women with high HBVL under antiviral or non-antiviral treatment, which may be used as markers for evaluating whether pregnant women with high HBVL may be free of antiviral treatment. This study may provide a basis for preventing potential adverse effects of antiviral treatment on maternal and fetal health.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1471-2393
1471-2393
DOI:10.1186/s12884-024-06907-z